Optune Lua (lung cancer treatment device)

2024: Product Announcement

On October 15, 2024, Novocure announced the Optune Lua wearable device for the treatment of metastatic non-small cell lung cancer (NSCLC). The product, according to the developer, is compact and usable.

NSCLC is one of the most common types of lung malignancies. The main risk factors are smoking, genetic predisposition, exposure to carcinogens, dusty polluted air, etc. In many patients, the disease is detected at an advanced stage, when complete removal of the tumor by surgical method is no longer possible.

𝓲

Novocure

Optune Lua therapy is based on the use of electric fields for the treatment of tumors (Tumor Treating Fields - TTFiields). Such fields affect the electrically charged components of cancer cells, disrupting their normal function, which can eventually lead to the death of these structures. As a result, the division of malignant cells slows or even stops completely, which inhibits the development of malignant formation.

The TTField fields are fed to the tumor region by a non-invasive medical device through so-called transducer arrays. The device is designed in such a way as not to interfere with the patient's daily activities and lead a normal lifestyle. Power is provided by the battery pack. Grates of transducers that are superimposed on the body are selected individually depending on gender, body type and neoplasm location. Optune Lua is recommended for 75% hours per day (18 hours). The device has received approval from the US Food and Drug Administration (FDA).^[1]

Notes